Transaction Overview 交易概览

•ArcScan, Inc. announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology Ltd. ("Haohai") that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc.

ArcScan, Inc. 宣布与上海昊海生物科技有限公司签署股权投资协议，获得1,115万美元的优先B轮投资。

•ArcScan, Inc. will help Haohai further develop their rapidly expanding offering of implantable lenses and, at the same time, provide ArcScan a base from which to expand into the largest ophthalmology market in the world.

ArcScan 将帮助昊海进一步发展植入式镜片相关业务，同时，昊海将为ArcScan产品的全球扩展提供了扎实的基础。

•Press Release Link: https://www.prnewswire.com/news-releases/arcscan-inc-signs-definitive-agreement-for-11-15-million-preferred-series-b-investment-with-shanghai-haohai-biological-technology-ltd-301338290.html

July 21, 2021 -- ArcScan, Inc., the developer of state-of-the-art ophthalmic ultrasound imaging device "ArcScan Insight® 100, " headquartered in Golden, Colorado, announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology Ltd. ("Haohai") that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc. Haohai is a leading Chinese ophthalmology and medical aesthetics company headquartered in Shanghai, and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SH) stock exchanges.

2021 年 7 月 21 日，作为眼前段超声成像设备“ArcScan Insight^® 100”的开发商 ArcScan, Inc.， 一家总部位于科罗拉多的领先眼科技术公司，宣布与上海昊海生物科技有限公司签署股票购买协议，促成对 ArcScan, Inc. 的 1,115 万美元优先 B 轮投资。 昊海是一家领先的中国眼科和医学美容公司，总部位于上海，并在香港 (6826.HK) 和上海 (688366.SH) 上市。

YAFO Capital (Shanghai) and Auctus Capital Partners (Chicago) acted as financial advisors on this transaction for ArcScan, Inc.

雅法资本 (YAFO Capital) 和 Auctus Capital Partners (Chicago) 担任 ArcScan, Inc. 此次交易的财务顾问。

“YAFO quickly brought us well qualified investor candidates that fit our space quite well and have persisted to bring them to the negotiating table. YAFO team have been a great team for us. We collaborate well, not always agreeing at first but with good listening skills we agree in the end on next steps. YAFO brings to ArcScan the important details of the not only the Chinese culture but also of the particular company smoothing the way for productive negotiations.”

--- Andrew Levien, CEO and President of ArcScan, Inc.

“雅法精准快速的帮助我们对接到了眼科领域高质量的潜在合作伙伴，并很好的领导了谈判过程。 我们与雅法团队的合作非常愉快。 虽然在个别问题上一开始我们会持不同意见，但雅法团队善于倾听和沟通，我们最终总能达成一致。 在交易中，雅法协助ArcScan更好的理解了合作双方在文化上的差异以及合作方的一些独特诉求，这为后续的顺利谈判铺平了道路。”

--- ArcScan, Inc. 首席执行官兼总裁 Andrew Levien

"This transaction fits well with our long-term global strategy in ophthalmic markets. The breakthrough technology from ArcScan, Inc. not only meets the unmet medical needs in the ophthalmic imaging field, but also leverages with our global product portfolio to significantly improve post-surgical results in premium IOLs and PIOL implantations." said Olivia Chen, Executive Director of Haohai Biological Technology Co. Ltd.

“此次交易非常有助于我们在眼科市场的长期全球战略布局。来自 ArcScan, Inc. 的突破性技术不仅满足了我们在眼科成像领域未满足的医疗需求，而且完善了我们的全球产品组合，显著改善了 premium IOL 和 PIOL 植入的术后效果。”昊海生物科技有限公司执行董事 Olivia Chen 称。

“We are thrilled to be a close partner with Haohai to help them further develop their rapidly expanding offering of implantable lenses and, at the same time, provide ArcScan a base from which to expand into the largest ophthalmology market in the world. This couldn‘t be a better strategic fit.” said Andrew Levien, CEO and President of ArcScan, Inc.

“我们很高兴能与昊海成为密切的合作伙伴，帮助他们进一步开发植入式镜片业务相关产品，同时也为 ArcScan 扩展到世界上最大的眼科市场打下基础。没有比这更好的的战略契合了。ArcScan, Inc. 首席执行官兼总裁 Andrew Levien 称。

ArcScan's Technology ArcScan的技术

The ArcScan Insight^® 100 imaging technology provides unmatched accuracy to obtain measurements in the entire anterior chamber of the eye. The device and software create a powerful platform that enables users to easily obtain stunning high-resolution images of the entire anterior segment in micron precision, including areas that cannot be imaged with current optical technologies. The Swept Beam Liquid Interface™ technology delivers dramatic developments in ultrasound imaging, unrivaled in its precision.

ArcScan Insight^® 100 成像技术提供极高的准确性，可以在整个眼睛前房中进行测量。 该设备和软件平台能使用户能以微米精度轻松获得整个眼球前部的超高分辨率图像，包括当前光学技术无法成像的区域。 Swept Beam Liquid Interface™ 技术在超声成像方面取得了巨大的发展，其精度无与伦比。

The ArcScan Insight^® 100 uses core proprietary technology that was originally developed and patented at Columbia/Weill University. A mechanically controlled 50 MHz transducer scans the eye in an arc shaped motion with a curvature that approximates the anterior ocular surface.

ArcScan Insight^® 100 的技术最早来源于哥伦比亚/威尔大学。 该设备以机械控制的 50 MHz 换能器以弧形运动扫描眼睛，其曲率接近眼前段的表面曲度。

ArcScan's Insight^® 100

The ArcScan Insight^® 100 device is a precision, very-high-frequency ultrasound ("VHF-US") device for imaging and measuring anterior chamber depth, angle-to-angle width, individual corneal layers, sulcus-to-sulcus width, and more—all with micron-level precision.

ArcScan Insight^® 100 设备是一种精密的超高频超声 (“VHF-US”) 设备，用于成像和测量前房深度、角到角宽度、单个角膜层、沟到沟宽度、以及更多——均具有微米级精度。

While the patient is comfortably seated and resting on an EyeSeal Disposable, the device scans the eye, non-invasively. ArcScan's EyeSeal Disposables are used to enable the precision imaging while preventing cross-contamination between patients. Designed for functional efficiency and ease of use, the ArcScan Insight^® 100 system is comprised of four main components: the ArcScan Insight^® 100 Device, the Insight software package, the fluidics module, and the electronics unit.

当患者舒适地坐在 EyeSeal Disposable 上时，该设备会无创地扫描眼睛。 ArcScan 的 EyeSeal Disposables 用于实现精确成像，同时防止患者之间的交叉感染。 ArcScan Insight^® 100 系统旨在实现功能效率和易用性，由四个主要组件组成：ArcScan Insight^® 100 设备、Insight 软件包、流体模块和电子单元。

The ArcScan Insight^® 100 provides accurate biometry for pre–operative and post-operative IOL, premium IOL, and ICL. This allows the clinic to evaluate accurate lens position, tilt, and volume.

ArcScan Insight^® 100 为术前和术后 IOL、premium IOL 和 ICL 提供准确的生物测量。这允许诊所进行准确的晶状体位置、倾斜度和体积评估。

"The goal is to reduce lens exchanges and make them very rare, as opposed to the current 2% exchange rate," says Dr. Dan Reinstein, Founder and Laser Eye Surgeon of London Vision Clinic and Chief Medical Officer of ArcScan. "The most advanced method for ICL sizing is to use the Insight 100 very-high-frequency digital ultrasound scanner to directly measure the area inside the eye, behind the iris where the lens will sit."

“我们的目标是减少镜片更换到几乎不更换，而不是目前的2%更换率，”伦敦眼科诊所创始人、激光眼科外科医生兼 ArcScan 首席医疗官 Dan Reinstein 博士说。 “最先进的 ICL 尺寸测量方法是使用 Insight 100 超高频数字超声扫描仪直接测量眼睛内部的区域，即镜片所在的虹膜后面。”

About ArcScan, Inc.

ArcScan develops smart imaging technology and continually evolving ultrasound to provide ophthalmologists with new insights into the true anatomy of the anterior segment of the eye, including areas behind the iris. ArcScan's mission is to enable better medicine in ophthalmology by driving improved outcomes in refractive, corneal, cataract, and glaucoma surgeries.

ArcScan 旨在开发智能成像技术和不断更新的超声技术，为眼科医生对眼睛前端的真实解剖结构提供最新的成像技术，包括虹膜后面的区域。 ArcScan 的使命是通过不断的改善屈光、角膜、白内障和青光眼手术的效果，在眼科领域实现价值。

About Shanghai Haohai Biological Technology Co., Ltd. 昊海生物科技有限公司

Haohai Biological Technology Co., Ltd. is a leading company in the PRC focusing on the research and development and manufacturing and sales of biomedical materials. Haohai strategically targets fast-growing therapeutic areas including ophthalmology, medical aesthetics and wound care, orthopedics and anti-adhesion, and hemostasis.

昊海生物科技成立于2007年，是一家专注于研发、生产及销售医用生物材料的高科技生物医药企业。公司于2015年4月30日于香港联交所主板成功上市，并于2019年10月30日在科创板上市（股票代码：06826.HK，688366.SH），成为首家“H+科创板”生物医药企业。公司策略性地专注于中国医用生物材料市场中快速增长的治疗领域，包括眼科、整形美容与创面护理、骨科、防粘连及止血。

About YAFO Life Sciences 雅法全球医疗

YAFO Life Sciences (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗（YAFO Life Sciences）是雅法资本旗下的医疗大健康部门，专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作；为中国医疗企业提供产品全球授权、海外市场研究服务，寻找海外投资并购标的，及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验；雅法庞大的海外的区域合伙人团队，均具20+年医药行业及交易经验，覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系：黎琦 | BD Director | 13621979227 | qli@yafocapital.com

Recent Transaction

YAFO Upcoming Events - ACCESS CHINA Biotech Forum -Winter Showcase (January 4-13, 2021, @JPM Week 2022)

雅法药通中国冬季路演活动将于2022年1月JPM WEEK期间举行。

Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.